Barry E. Rosenbloom

4.6k citations

51 papers · 2.5k indexed · h-index 24

Impact in

Physiology top 0.5%
- Lysosomal Storage Disorders Research
Cell Biology top 1%
- Cellular transport and secretion

Papers in

Physiology 37
- Lysosomal Storage Disorders Research 36
Cell Biology 16
- Cellular transport and secretion 16

Co-authors: Neal J. Weinreb Joel Charrow Pramod K. Mistry Edwin H. Kolodny Gregory M. Pastores Paige Kaplan Hans C. Andersson Rebecca S. Wappner
Journals: Blood (6 papers)Molecular Genetics and Metabolism (5 papers)American Journal of Hematology (4 papers)Genetics in Medicine (3 papers)Critical Reviews™ in Oncogenesis (3 papers)
Partner nations: United States United Kingdom Argentina

In The Last Decade

Barry E. Rosenbloom

50 papers receiving 2.4k citations

Peers

Countries citing papers authored by Barry E. Rosenbloom

Since Specialization

Citations

This map shows the geographic impact of Barry E. Rosenbloom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barry E. Rosenbloom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barry E. Rosenbloom more than expected).

Fields of papers citing papers by Barry E. Rosenbloom

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barry E. Rosenbloom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barry E. Rosenbloom. The network helps show where Barry E. Rosenbloom may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Barry E. Rosenbloom, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Barry E. Rosenbloom Line = papers co-authored together Barry E. Rosenbloom links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Challenges in Gaucher disease: Perspectives from an expert panel Molecular Genetics and Metabolism ·Gregory A. Grabowski, Priya S. Kishnani, Roy N. Alcalay, S. Grace Prakalapakorn, Barry E. Rosenbloom, Paige DiGirolamo, Neal J. Weinreb	2025	3
2	Gaucher disease and SARS-CoV-2 infection: Emerging management challenges Molecular Genetics and Metabolism ·Pramod K. Mistry, Manisha Balwani, Deborah Barbouth, T. Burrow, Edward I. Ginns, Özlem Göker-Alpan, Gregory A. Grabowski, Reena V. Kartha, Priya S. Kishnani, Heather Lau, G. S. Brichi, Grisel Lopez, Gustavo Maegawa, Seymour Packman, Carlos E. Prada, Barry E. Rosenbloom, Imre Karácson, Annie Lunt, Neal J. Weinreb, Ellen Sidransky	2020	23
3	Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial The Lancet ·Timothy M. Cox, Guillermo Drelichman, Sarah B. Mollo, Manisha Balwani, Thomas Andrew Burrow, Ana María Martins, Elena Lukina, Barry E. Rosenbloom, Leorah Ross, Jennifer Angell, Ana Cristina Puga	2015	118
4	Evaluation of disease burden and response to treatment in adults with type 1 gaucher disease using a validated disease severity scoring system (DS3) Orphanet Journal of Rare Diseases ·Neal J. Weinreb, David N. Finegold, Eleanor Feingold, Zhen Zeng, Barry E. Rosenbloom, Suma P. Shankar, Dominick Amato	2015	31
5	Bone disease in patients with Gaucher disease Expert Review of Endocrinology & Metabolism ·Barry E. Rosenbloom, Neal J. Weinreb	2014	2
6	Encore: A Randomized, Controlled, Open-Label Non-Inferiority Study Comparing Eliglustat To Imiglucerase In Gaucher Disease Type 1 Patients On Enzyme Replacement Therapy Who Have Reached Therapeutic Goals Blood ·Manisha Balwani, Timothy M. Cox, Guillermo Drelichman, Sarah B. Mollo, Ana María Martins, Elena Lukina, Barry E. Rosenbloom, Leorah Ross, Jennifer Angell, Ana Cristina Puga	2013	5
7	A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability Genetics in Medicine ·Gregory M. Pastores, Barry E. Rosenbloom, Neal J. Weinreb, Özlem Göker-Alpan, Gregory A. Grabowski, Gabriel Cohn, David M. Zahrieh	2013	26
8	Gaucher Disease: A Comprehensive Review Critical Reviews™ in Oncogenesis ·Barry E. Rosenbloom, Neal J. Weinreb	2013	121
9	Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa Molecular Genetics and Metabolism ·Ans T. van der Ploeg, Richard J. Barohn, Lisa Carlson, Joel Charrow, Paula R. Clemens, Robert J. Hopkin, Priya S. Kishnani, Pascal Laforêt, Claire Morgan, Sharon Nations, Alan Pestronk, Horacio Plotkin, Barry E. Rosenbloom, Katherine B. Sims, Elisa Tsao	2012	85
10	The incidence of Parkinsonism in patients with type 1 Gaucher disease: Data from the ICGG Gaucher Registry Blood Cells Molecules and Diseases ·Barry E. Rosenbloom, Manisha Balwani, Jeff M. Bronstein, Edwin H. Kolodny, Swati Sathe, A. R. Gwosdow, John S. Taylor, J. Alexander Cole, Ari Zimran, Neal J. Weinreb	2010	110
11	Primary hepatic carcinoid tumor presenting as Cushing’s syndrome Journal of Endocrinological Investigation ·佐藤夏世, Hitalo Cavalcanti Vasconcelos, 昌直橋本, Steven D. Colquhoun, Barry E. Rosenbloom, Luc Van lmpe, Stephen A. Geller, Mamoun Younes, Juan Lechago, Anthony P. Heaney	2007	25
12	Imiglucerase (Cerezyme^®) improves quality of life in patients with skeletal manifestations of Gaucher disease Clinical Genetics ·Neal J. Weinreb, J. A. Barranger, Seymour Packman, Ainu Prakash‐Cheng, Barry E. Rosenbloom, Katherine B. Sims, Jennifer Angell, Alison Skrinar, GM Pastores	2007	76
13	Individualization of long-term enzyme replacement therapy for Gaucher disease Genetics in Medicine ·Hans C. Andersson, Joel Charrow, Paige Kaplan, Pramod K. Mistry, Gregory M. Pastores, Erind Hoti, Barry E. Rosenbloom, C. Ronald Scott, Rebecca S. Wappner, Neal J. Weinreb	2005	89
14	Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations The Journal of Pediatrics ·Joel Charrow, Hans C. Andersson, Paige Kaplan, Edwin H. Kolodny, Pramod K. Mistry, Gregory M. Pastores, Ainu Prakash‐Cheng, Barry E. Rosenbloom, C. Ronald Scott, Rebecca S. Wappner, Neal J. Weinreb	2004	82
15	Gaucher disease with nephrotic syndrome: Response to enzyme replacement therapy American Journal of Kidney Diseases ·Domenico Santoro, Barry E. Rosenbloom, Arthur H. Cohen	2002	18
16	Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry The American Journal of Medicine ·Neal J. Weinreb, Joel Charrow, Hans C. Andersson, Paige Kaplan, Edwin H. Kolodny, Pramod K. Mistry, Gregory M. Pastores, Barry E. Rosenbloom, C. Ronald Scott, Rebecca S. Wappner, Ari Zimran	2002	404
17	The Gaucher Registry Archives of Internal Medicine ·Joel Charrow, Hans C. Andersson, Paige Kaplan, Edwin H. Kolodny, Pramod K. Mistry, Gregory M. Pastores, Barry E. Rosenbloom, C. Ronald Scott, Rebecca S. Wappner, Neal J. Weinreb, Ari Zimran	2000	398
18	Proposing a new standard to establish medical competence for the purpose of critical care intervention Critical Care Medicine ·Cory Franklin, Barry E. Rosenbloom	2000	9
19	Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphoma Investigational New Drugs ·Steven L. Allen, Lee Schacter, Stuart M. Lichtman, Ronald M. Bukowski, Dahlene N. Fusco, Martee L. Hensley, Peter J. O’Dwyer, Abraham Mittelman, Barry E. Rosenbloom, Halavath Tharunkumar	1996	10
20	A Less Costly Regimen of Alglucerase to Treat Gaucher's Disease New England Journal of Medicine ·I Kadek Dwi Putra, Barry E. Rosenbloom, Andrea Kay, Paul Garver, Dennis Thurston, James A. Koziol, Terri Gelbart, Ernest Beutler	1992	105

About Barry E. Rosenbloom

Barry E. Rosenbloom is a scholar working on Physiology, Cell Biology, Organic Chemistry, Physiology and Genetics, having authored 51 papers that have together received 2.5k indexed citations. Recurring topics across this work include Lysosomal Storage Disorders Research (36 papers), Cellular transport and secretion (16 papers), Carbohydrate Chemistry and Synthesis (14 papers), Glycosylation and Glycoproteins Research (9 papers), Trypanosoma species research and implications (8 papers), Studies on Chitinases and Chitosanases (5 papers), Glycogen Storage Diseases and Myoclonus (3 papers) and Chronic Lymphocytic Leukemia Research (3 papers). The work is most often cited by research in Physiology (2.1k citations), Cell Biology (1.0k citations), Organic Chemistry (786 citations), Physiology (119 citations) and Epidemiology (904 citations). Barry E. Rosenbloom has collaborated with scholars based in United States, United Kingdom and Argentina. Frequent co-authors include Neal J. Weinreb, Joel Charrow, Pramod K. Mistry, Edwin H. Kolodny, Gregory M. Pastores, Paige Kaplan, Hans C. Andersson, Rebecca S. Wappner, C. Ronald Scott and Ari Zimran. Their work appears in journals such as Blood, Molecular Genetics and Metabolism, American Journal of Hematology, Genetics in Medicine and Critical Reviews™ in Oncogenesis.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact